Hepatocellular carcinoma (HCC) is the sixth leading cause of cancer globally (fifth in men and eighth in women) with 750,000 new cases per year. Its global prognosis is very poor with only a 7% 5-year survival. Because of such a poor survival rate, at 696,000 deaths, it is currently the third leading cause of cancer mortality after lung and stomach cancer. Within 5 years, global HCC mortality is expected to be second only to lung cancer.

In the United States (U.S.), while primary HCC is small at ~20,000 cases, it is one of the few U.S.-based cancers whose death rate is rising, primarily due an increase in hepatitis C and obesity induced nonalcoholic steatohepatitis (NASH). U.S. 5-year survival rates have improved only marginally in the past 40 years, from 4% in the early 70s to 14% currently, second only to pancreatic cancer, which has a 6% survival rate.

Eighty percent of HCC cases arise in developing countries and over 55% of all HCC cases are found in mainland China. Asia has a high incidence of chronic viral hepatitis infection (hepatitis B or C), which contributes to the high rate of HCC. Liver cirrhosis, a late-term effect of hepatitis infection, results in a 10-fold risk in HCC, hence the high Asian risk factor.

Like lung cancer, HCC is a silent disease whose effects typically do not show up until late stage presentation. Early-stage diagnosis gives a poor 5-year survival of 26%, whereas late-stage diagnosis gives a miserable 2% survival.

Invasive therapies
Invasive therapies that can improve on the 5-year survival of HCC include resection and transplantation. Their improvement in 5-year survival rates range from 30% to 50% and 60% to 70%, respectively. These surgical techniques, first developed in 1949 and 1967, are unfortunately eligible to <30% of HCC patients due to multiple factors, including tumor size and location within the liver, vascular invasion, and poor liver function.

Further, in several large key Asian societies, transplantation is neither culturally acceptable nor clinically practical. Some less invasive treatments include: percutaneous ethanol injection (PEI), transarterial chemo embolization (TACE), radiofrequency ablation (RFA) and yttrium-90 brachytherapy, but these are either only palliative or suffer from many of the same eligibility contraindications as surgery.

Treatment challenges
Treating the liver for HCC using any technique is a challenge for two reasons. Firstly, it is two diseases in one: a chronic viral liver disease and a malignancy resulting from that chronic liver destruction. Secondarily, the heterogeneity (etiology and prognosis) of those different diseases affects treatment and survival.

Tumor stage and underlying liver function are both major determinants of the treatment selection as well as prognosis in HCC patients, thus allowing no
more than a 20% chance for potentially curative therapies.\(^9\) The accurate assessment of disease differential, disease extent, and liver function significantly impacts the choice and targeting of treatment. Key to the safe treatment of liver disease is the preservation of liver function.\(^9\)

Lessons learned from surgery provide a model for treating with radiation. In surgery, assessment is done using a variety of metrics to assess liver function and being cognizant of liver volume treated. Assessment metrics include: Child-Pugh (CP) score\(^10\) — a liver function classification system, A to C, scoring severity of disease, CT perfusion, Model for End-Stage Liver Disease (MELD) and Barcelona Clinic Liver Cancer (BCLC) staging.\(^11\) In liver surgery for HCC, preservation of function dictates resections of no more than 0.5% of body weight and 45% of liver volume (~450cc) and resections are only performed when a variety of liver function measures, such as a CP score of no worse than class A, are met. The relationship between CP liver function and BCLC staging is nicely detailed in a recent review paper from Korea.\(^12\)

**SBRT for HCC: Early efforts and rationale**

The liver was first a target for radiation therapy as early as 1924. The use of conventional external beam radiation therapy (RT) as a curative technique, was hampered by early evidence of radiation’s severe toxicity to the diseased liver defined as radiation-induced liver disease (RILD).\(^10,13\) RILD manifests in long-term migration of Child-Pugh score from A to B to C, resulting in likely liver failure with the later scores. A decline in liver function is more likely in patients with higher baseline CP scores and in those with advanced disease requiring larger volumes of irradiated liver.\(^14\)

Thus all forms of RT for HCC have been slower to evolve due to the liver’s low tolerance to RT, further reduced in the cirrhotic liver. This is especially true where high doses of radiation are distributed throughout the liver as is the case with non-image-guided, non-IMRT treatments. Palliative liver radiation has recently been shown to improve quality of life in patients with active symptoms from HCC or liver metastases.\(^15\)

Liver SBRT, the precise delivery of potent doses of radiation in a small number of fractions to the liver, was first performed by Blomgren & Lax in 1995 in 1 to 3 fractions of 20 to 45 Gy.\(^16\) SBRT is the non-CNS extracranial extension of
Table 1. Recent Studies on Treatment of Early-Stage Hepatocellular Carcinoma (HCC) with Stereotactic Body Radiation Therapy (SBRT)

<table>
<thead>
<tr>
<th>Author &amp; Center</th>
<th>Patients Treated</th>
<th>Gross Tumor Volume</th>
<th>Dose Range</th>
<th>Median Follow-up</th>
<th>Local Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Year)</td>
<td>(initial CP score)</td>
<td>(cc)</td>
<td>(range &amp; med)</td>
<td>(fx per tmt)</td>
<td>(range)</td>
</tr>
<tr>
<td>Sanuki25</td>
<td>185</td>
<td>7.6 cc</td>
<td>35 – 44 Gy</td>
<td>[1.5 – 65]</td>
<td>25 mo</td>
</tr>
<tr>
<td>Tokai U (Aug 13)</td>
<td>(A=158, B=27)</td>
<td>[2 – 112]</td>
<td>[40 Gy med]</td>
<td>[in 3 or 4 fx]</td>
<td>[1-24]</td>
</tr>
<tr>
<td>Andolino24</td>
<td>60</td>
<td>29 cc</td>
<td>24 – 48 Gy</td>
<td>[3-80]</td>
<td>27 mo</td>
</tr>
<tr>
<td>Indiana Univ (Nov 11)</td>
<td>(A=36, B=24)</td>
<td>[2 – 112]</td>
<td>[40 Gy med]</td>
<td>[in 3 or 4 fx]</td>
<td>[1-24]</td>
</tr>
<tr>
<td>Louis23</td>
<td>25</td>
<td>45 cc</td>
<td>45 Gy</td>
<td>[18-100]</td>
<td>12.7 mo</td>
</tr>
<tr>
<td>Liege Univ (Oct 10)</td>
<td>(A=22, B=3)</td>
<td>(18-100)</td>
<td>[3 fx]</td>
<td>[1-24]</td>
<td></td>
</tr>
<tr>
<td>Kwon22</td>
<td>42</td>
<td>15.4 cc</td>
<td>30 – 39 Gy</td>
<td>[3-82]</td>
<td>27.8 mo</td>
</tr>
<tr>
<td>Catholic U (Sept 10)</td>
<td>(A=38, B=4)</td>
<td>[3-82]</td>
<td>[33 Gy med]</td>
<td>[in 3 or 4 fx]</td>
<td>[8.4-49.1]</td>
</tr>
<tr>
<td>Seo21</td>
<td>38</td>
<td>40.5 cc</td>
<td>33 – 57 Gy</td>
<td>[11-464]</td>
<td>15 mo</td>
</tr>
<tr>
<td>KCCH (Sept 10)</td>
<td>(A=34, B=4)</td>
<td>[11-464]</td>
<td>[3 or 4 fx]</td>
<td>(3-47)</td>
<td></td>
</tr>
<tr>
<td>Cardenes18</td>
<td>17</td>
<td>34 cc</td>
<td>36 – 48 Gy</td>
<td>[8-95]</td>
<td>18 mo</td>
</tr>
<tr>
<td>Indiana U (Mar 10)</td>
<td>(A=6, B=11)</td>
<td>[8-95]</td>
<td>[in 3 or 5 fx]</td>
<td>(3-47)</td>
<td></td>
</tr>
<tr>
<td>Tse19</td>
<td>31</td>
<td>173 cc</td>
<td>24 – 54 Gy</td>
<td>[9-1913]</td>
<td>17.6 mo</td>
</tr>
<tr>
<td>PMH (Feb 08)</td>
<td>(A=31, B=0)</td>
<td>[9-1913]</td>
<td>[36 Gy med]</td>
<td>[in 6 Fx]</td>
<td>(10.8-39.2)</td>
</tr>
</tbody>
</table>

RILD = Radiation Induced Liver Disease; NR = Not Reported; K-M = Kaplan-Meier; OR = Overall Response; CR = Complete Response; PR = Partial Response; SD = Stable Disease; PFS = Progression Free Survival

* These seven studies represent single institution peer review papers on SBRT for HCC where there were at least 15 (17 to 185) consecutive HCC patients being studied.

* Survival values are based on Kaplan – Meyer probability graphs reporting on the percentage of patients alive after a specific time period, reported as %-alive after y-years.

* Child Pugh (CP) classifies (A, B, or C) severity of pre-treatment liver disease by scoring (1, 2, or 3), five liver health criteria; more points yields poorer status

[s6=A, 7-9=B, ≥10=C]

Toxicity: Radiation Induced Liver Disease (RILD) is a dose limiting complication of conventional liver radiation, because the entire liver gets radiated. These SBRT studies show that by employing focused stereotactic treatments, high doses of radiation can be safely and effectively delivered with excellent RILD results. Only one of the 7 studies reported any significant RILD after 3 months and that was in 3/17 patients, or 18%.

Most studies reported 0% late term toxicity of greater than Grade 2. Only two studies reported any post treatment CP progression (A>B and/or B>C).
### Table 1. Recent Studies on Treatment of Early-Stage Hepatocellular Carcinoma (HCC) with Stereotactic Body Radiation Therapy (SBRT)

<table>
<thead>
<tr>
<th>Study</th>
<th>Overall Survival</th>
<th>Toxicity &gt; Grade 2</th>
<th>RILD (%)</th>
<th>Child-Pugh</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K-M (% at yr)</td>
<td>(%) late</td>
<td>(%) of patients</td>
<td>[change (decline) in CP score]</td>
<td></td>
</tr>
<tr>
<td>95, 83 &amp; 70 at 1, 2 &amp; 3 yr</td>
<td>13%</td>
<td>10.3%</td>
<td>NR</td>
<td>• TACE performed in 111 patients prior to SBRT. • 19 (10.3%) had a decline in CP score by 2 points. • Grade 5 failures were observed in 1% (CP-B only).</td>
<td></td>
</tr>
<tr>
<td>67 at 2 yr</td>
<td>15%</td>
<td>NR</td>
<td>A&gt;B: 7/36 B&gt;C: 5/24</td>
<td>• CP-A patients had a 1-yr 93% LC and 93% OS. • CP-B patients had a 1-yr OS of 70%. • 23 patients proceeded to transplant.</td>
<td></td>
</tr>
<tr>
<td>79, 52 at 1 &amp; 2 yr</td>
<td>8%</td>
<td>0%</td>
<td>NR</td>
<td>• Median DFS was 15.8 mo. CP-A patients had an actuarial survival of 86% vs 33% for CP-B patients. • OR=85%, CR=28%, PR=28%, SD=14% for 14 evaluable patients.</td>
<td></td>
</tr>
<tr>
<td>93, 77 &amp; 59 at 1, 2 &amp; 3 yr</td>
<td>2%</td>
<td>2%</td>
<td>NR</td>
<td>• Salvage SBRT for patients who failed repeat TACE. • OR=71.9%, CR=59.6%, PR=26.2%</td>
<td></td>
</tr>
<tr>
<td>69, 61 &amp; 42 at 1, 2 &amp; 3 yr</td>
<td>3%</td>
<td>0%</td>
<td>NR</td>
<td>• All tumors &lt; 8cm Ø: LR= 63%; CR=2.6% • PR=60.5%; SD= 28.9%; 7.9%=PD • 2 yr PFS=66.4%</td>
<td></td>
</tr>
<tr>
<td>75 &amp; 60 at 1 &amp; 2 yr</td>
<td>23%</td>
<td>18%</td>
<td>NR</td>
<td>• OR=75%; 6 patients proceeded to transplant; 10 patients alive at 24 mo. med FU • No RILD was found in CP-A patients, but 27% (3/11)of CP-B patients had RILD</td>
<td></td>
</tr>
<tr>
<td>48 at 1 yr</td>
<td>29%</td>
<td>0%</td>
<td>A&gt;B: 5/31</td>
<td>• Dose escalation study. • Median survival 11.7 mo OR=49%. • No RILD but 16% had a decline in CP score</td>
<td></td>
</tr>
</tbody>
</table>
stereotactic radiosurgery (SRS), which neurosurgeons have been using for ablation of tumors in the brain and spine for >30 and >10 years, respectively. For primary CNS tumors, the intent is primarily curative. With very high dose rates per session, SRS and SBRT treatments require precision with tight margins to the tumor and minimum dose to surrounding organs at risk and normal tissues and employ an overwhelmingly ablative radiobiological mechanism. This is in contrast to conventional RT treatments where cells are allowed to repopulate and precision requirements are an order of magnitude less stringent.

The advantage of refined SBRT techniques is that they allow for a safer administration of higher levels of dose while minimizing the potential of RILD. The past decade has seen a small number of single institution SBRT liver trials every couple of years on various platforms (Figure 1). Klein pointed out that there has been a doubling to 600 publications, on the use of radiation to treat liver tumors, in the 5-year period “2005-2010,” over the prior 5-year period. Furthermore, over 75% of all SBRT for HCC studies have published in the last 6 years, and over 66% published in the past 3 years.

Refinements in SBRT HCC treatments have led to substantially improved results over both RT and those early SBRT treatments, which had some grade of liver function measured by a decline in CP score. No patients had RILD and this study set the stage for other SBRT studies, as previously RILD was considered a treatment limiting toxicity of conventional radiation treatments.

A group from Indiana reported on 17 patients with 1 to 3 targets (25 HCC total). They had a dose escalation trial delivering 36 to 48 Gy in fractionation schedules from 5x8 Gy to 3x16 Gy. Their tumors (cumulative diameter ≤ 6 cm) were much smaller with an average GTV of 34 cc. With a mean follow up of 18 months, they achieved 100% LC at 1-year and an OS of 75% and 60% at 1 and 2 years respectively. Three patients had grade 3 to 4 toxicity. RILD was not observed in any CP-A patients, but was observed in 27% of CP-B patients.

One Korean group documented a prospective registry of 38 patients with tumors < 10 cc treated in 33-57 Gy in 3 to 4 fractions. One- and 2-year LC was 79% and 66% and 1-, 2- and 3-year OS was 68%, 61% and 41%, respectively. Only one grade-3 skin toxicity was reported. For those 26 patients who received a dose of > 42 Gy, a 2-year OS was reached.

Another Korean group documented 42 HCC patients with a median GTV of 15.4 cc, treated with a median dose of 33 Gy (30 to 39 Gy) in 3 fractions. With a median follow up of 27.8 months, they achieved a LC of 72 and 67.5% at 1 and 2 years respectively and OS of 92.9, 77.3 and 58.6% at 1, 2 and 3 years respectively. Consistent with other SBRT studies, they had very low toxicity (< 2 %) and low incidence of radiation induced liver disease RILD (2%).

A Belgian group reported on 25 HCC patients treated with a median dose of 45 Gy in 3 sessions. The treatment was well tolerated overall, and there were no grade 4 toxicities. Overall, actuarial survival was 79% and 52% at 1 and 2 years with a mean overall follow up of 12.7 months. CP-B patients had a 33% actuarial survival versus CP-A patients at 86%. No RILD was observed and excellent response to treatment was observed with overall response of 85% in 14 evaluable patients.

In the largest North American study to date, a paper reported on 60 patients treated with an average GTV of 29 cc. 36 CP-A patients were treated with 30 to 48 Gy in 3 fractions. With a median follow-up of 27 months, they achieved a 1-year LC of 93% and a 1-, 2- and 3-year OS of 93%, 77% and 70%, respectively. 19% had a decline in CP score and 2 patients had grade 5 toxicities. The same paper further reports on 24 patients with CP-B scores treated with 24 to 48 Gy in 3 fractions whose 1-, 2- and 3-year OS were reduced to 70%, 50% and 50%, respectively. Of the 60 patients, 23 went on to othotopic liver transplant (OLT).

Several even larger studies have more recently been reported from across Asia. The largest single study to date is from Japan. In this study, 221 patients with 237 single small HCC lesions were treated from 2005 to 2012. Of these, 185 met a variety of clinical criteria and were evaluable in this study. Patients were treated with either 35 Gy (48 pts) or 40 Gy (137 pts) depending on the CP scores and other factors. The 3-year local control and overall survival rates were 91% and 70% respectively. Ten local recurrences were observed at a median of 21 months. The dosing

SBRT for HCC: Recent studies

A number of centers have recently reported on SBRT-based HCC treatment and several are summarized in Table 1.

- A Toronto group reported on a phase I liver cancer dose-escalation trial, which included 31 HCC patients with an average gross tumor volume (GTV) of 173 cc [9 to 1913 cc]. With a median dose of 36 Gy (24 to 54 Gy) in 6 fractions, they achieved a 12-month local control (LC) rate of 65%. For patients with portal vein thrombosis (PVT), median survival was 11.6 months, which improved to 17.2 months for patients with no PVT. Overall survival (OS) was 48% at 1-year and 16% (5/31) of patients had a poorer level of liver function measured by a decline in CP score. No patients had RILD and this study set the stage for other SBRT studies, as previously RILD was considered a treatment limiting toxicity of conventional radiation treatments.

- A group from Indiana reported on 17 patients with 1 to 3 targets (25 HCC total). They had a dose escalation trial delivering 36 to 48 Gy in fractionation schedules from 5x8 Gy to 3x16 Gy. Their tumors (cumulative diameter ≤ 6 cm) were much smaller with an average GTV of 34 cc. With a mean follow up of 18 months, they achieved 100% LC at 1-year and an OS of 75% and 60% at 1 and 2 years respectively. Three patients had grade 3 to 4 toxicity. RILD was not observed in any CP-A patients, but was observed in 27% of CP-B patients.

- One Korean group documented a prospective registry of 38 patients with tumors < 10 cc treated in 33-57 Gy in 3 to 4 fractions. One- and 2-year LC was 79% and 66% and 1-, 2- and 3-year OS was 68%, 61% and 41%, respectively. Only one grade-3 skin toxicity was reported. For those 26 patients who received a dose of > 42 Gy, a 2-year OS was reached.

- Another Korean group documented 42 HCC patients with a median GTV of 15.4 cc, treated with a median dose of 33 Gy (30 to 39 Gy) in 3 fractions. With a median follow up of 27.8 months, they achieved a LC of 72 and 67.5% at 1 and 2 years respectively and OS of 92.9, 77.3 and 58.6% at 1, 2 and 3 years respectively. Consistent with other SBRT studies, they had very low toxicity (< 2 %) and low incidence of radiation induced liver disease RILD (2%).

- A Belgian group reported on 25 HCC patients treated with a median dose of 45 Gy in 3 sessions. The treatment was well tolerated overall, and there were no grade 4 toxicities. Overall, actuarial survival was 79% and 52% at 1 and 2 years with a mean overall follow up of 12.7 months. CP-B patients had a 33% actuarial survival versus CP-A patients at 86%. No RILD was observed and excellent response to treatment was observed with overall response of 85% in 14 evaluable patients.

- In the largest North American study to date, a paper reported on 60 patients treated with an average GTV of 29 cc. 36 CP-A patients were treated with 30 to 48 Gy in 3 fractions. With a median follow-up of 27 months, they achieved a 1-year LC of 93% and a 1-, 2- and 3-year OS of 93%, 77% and 70%, respectively. 19% had a decline in CP score and 2 patients had grade 5 toxicities. The same paper further reports on 24 patients with CP-B scores treated with 24 to 48 Gy in 3 fractions whose 1-, 2- and 3-year OS were reduced to 70%, 50% and 50%, respectively. Of the 60 patients, 23 went on to othotopic liver transplant (OLT).

- Several even larger studies have more recently been reported from across Asia. The largest single study to date is from Japan. In this study, 221 patients with 237 single small HCC lesions were treated from 2005 to 2012. Of these, 185 met a variety of clinical criteria and were evaluable in this study. Patients were treated with either 35 Gy (48 pts) or 40 Gy (137 pts) depending on the CP scores and other factors. The 3-year local control and overall survival rates were 91% and 70% respectively. Ten local recurrences were observed at a median of 21 months. The dosing
sbm FOR EARLY-STAGE PRIMARY LIVER CANCER

APPLIED RADIATION ONCOLOGY

SEEPAGE 3 FOR DETAILS
CME

REFERENCES


December 2013
www.appliedradiationoncology

APPLIED RADIATION ONCOLOGY